Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of Baxter International Inc. Investors
November 14, 2019 16:00 ET
|
Glancy Prongay & Murray LLP
LOS ANGELES, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX)...
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation on Behalf of Baxter International Inc. Investors
November 14, 2019 12:45 ET
|
Law Offices of Howard G. Smith
BENSALEM, Pa., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors...
Bragar Eagel & Squire, P.C. Is Investigating Merit Medical Systems, Baxter International, Under Armour, and BeiGene on Behalf of Stockholders and Encourages Investors to Contact the Firm
November 06, 2019 10:58 ET
|
Bragar Eagel & Squire
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against Merit Medical Systems, Inc....
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation on Behalf of Baxter International Inc. Investors
November 05, 2019 12:17 ET
|
Law Offices of Howard G. Smith
BENSALEM, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors...
Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of Baxter International Inc. Investors
October 31, 2019 14:04 ET
|
Glancy Prongay & Murray LLP
LOS ANGELES, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX)...
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
March 18, 2015 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - March 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns...
Melinta Therapeutics Bolsters Executive Team with Appointment of Paul Estrem as Chief Financial Officer
December 02, 2013 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the appointment of Paul Estrem to the role of chief
financial officer. Mr. Estrem brings more than 20 years...